

Amendments to the Claims:

This listing will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 and 2 (cancelled)

Claim 3 (Currently amended): A purified peptide having anti-angiogenic functionality ~~of the~~
structure based on an amino acid sequence:

~~Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp~~ SEQ ID NO: 4

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus
(on the right);

wherein the ~~peptide sequence corresponds to the fourth peptide of peptides of GeneBank~~
~~LocusID:4018 which are separated by cysteine units,~~
and wherein at least one amino acid of said peptide is in a D-form.

Claim 4: A pharmaceutical composition comprising said peptide of claim 3.

Claim 5: (Currently amended): A purified peptide having anti-angiogenic functionality ~~of the~~
structure based on an amino acid sequence:

~~Arg Asn Pro Asp Gly Asp Ile Asn Gly Pro Trp~~ SEQ ID NO: 4

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);

wherein the ~~peptide sequence corresponds to the fourth peptide of peptides of GeneBank~~
~~LocusID:4018~~ which are separated by cysteine units, wherein one amino acid is removed, replaced,
or added to said peptide to form a new molecule

and wherein either a C-terminal protecting group or an N-terminal protecting group is removed from
the peptide.

Claim 6 (Currently amended): A purified pharmaceutical product comprising a peptide having anti-
angiogenic functionality of the structure based on an amino acid sequence:

~~Arg Asn Pro Asp Gly Asp Ile Asn Gly Pro Trp~~ SEQ ID NO: 4

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);

wherein the ~~peptide sequence corresponds to the fourth peptide of peptides of GeneBank~~ ~~LocusID:~~
~~4018~~ which are separated by cysteine units,

and wherein either a C-terminal protecting group or an N-terminal protecting group is removed from
the peptide.

Appl. No. 09/927,006
Response. Dated April 28, 2006
Reply to Office Action of November 28, 2006

Claim 7: The purified peptide according to claim 3, wherein either a C-terminal protecting group or an N-terminal protecting group is removed from the peptide.

Claim 8: A pharmaceutical product comprising said peptide of claim 7.

Claims 9-12 (cancelled)